Navigation Links
INFORM-1 Clinical Trial Amended to Further Explore Promising Direct Antiviral Regimen in HCV Patients
Date:4/21/2009

- Non-responder and Null Responder HCV patients -

- Twice-Daily Dosing and Higher Doses of ITMN-191 (R7227) -

BRISBANE, Calif., April 21 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced that the innovative clinical study of protease inhibitor ITMN-191 (R7227) in combination with nucleoside polymerase inhibitor R7128 (Roche/Pharmasset), referred to as the INFORM-1 study, has been successfully amended to include additional cohorts to explore the combination in treatment-experienced and null responder HCV patients. In addition, the amended protocol now includes the administration of twice-daily and higher-dose regimens of ITMN-191 in combination with R7128 in treatment-naive patients. A description of the expanded study design can be viewed at .

Dan Welch, Chairman, Chief Executive Officer and President of InterMune, said, "The first four cohorts of the INFORM-1 study successfully demonstrated that the novel combination of relatively low doses of two direct antiviral agents can be administered safely and, in the absence of interferon, result in robust antiviral activity in treatment-naive HCV patients. INFORM-1 has now been expanded to explore this novel regimen in treatment-experienced patients; both non-responder patients and so-called null responders, which together represent an important unmet medical need as their treatment options are currently very poor. The inclusion of twice-daily dosing of ITMN-191 at doses of up to 900mg, doses that were safely and effectively explored when combined with the current standard of care, is another important expansion of INFORM-1. We look forward to the results of these important new cohorts."

INFORM-1 Expanded Study Design

The expanded INFORM-1 design now includes three additional dosage cohorts
'/>"/>

SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. INFORM-1 Interim Results Accepted for Late-Breaker Presentation at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL)
2. InterMune and Pharmasset to Discuss INFORM-1 Results From EASL Conference, April 25
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
7. PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials
8. Clinical Data Acquires Epidauros Biotechnologie AG, Significantly Enhancing Proprietary Genetic Biomarker Portfolio
9. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
10. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
11. Lorus Advances Clinical Development of GTI-2040 Combined with Ara-C in Acute Myeloid Leukemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... CA (PRWEB) October 22, 2014 ... from Sartorius, A & D Weighing, Rice Lake, ... CPA Semi-Micro Balance . The Sartorius CPA Semi-Micro ... an affordable high-quality, precise, and user-friendly laboratory balance. ... of laboratory equipment, their laboratory balances are well ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 Physicians ... its cardiovascular pharmacogenetics menu, which enables healthcare providers ... With PCLS’s evidence-based results, healthcare providers are ... optimize their therapy, while minimizing risks for adverse ... U.S., according to the FDA [1] more than ...
(Date:10/22/2014)... ROCKVILLE, Md. , Oct. 22, 2014   ... company developing novel pathogen-specific therapies for serious infections and ... Office has issued a Notice of Allowance for a ... product in its C. difficile program, SYN-004. This ... to SYN-004 in the U.S. and adds to the ...
(Date:10/22/2014)... , Oct. 22, 2014 Nuvilex, Inc. (OTCQB: ... 400 million people worldwide are living with diabetes, with  ... by 2030.  The global market for diabetes treatments is ... 330,000 people worldwide died from pancreatic cancer.  Pancreatic cancer ... to cancer in the United States ...
Breaking Biology Technology:Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 2Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 3PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4Nuvilex Brief Analyst Report: Thinking Outside the Box by BrokerBank Securities, Inc. 2
... "Most Innovative" award by the Association of ... Chinese Canadian Entrepreneurs, ... a biotechnology company discovering and developing the next wave of,antibody ... Executive Officer, received the "Most Innovative" award at the,Chinese Canadian ...
... chemotherapy would welcome an advance promising to dramatically reduce ... researchers at Washington University School of Medicine in St. ... , The researchers focused a powerful drug directly on ... a drug dose 1,000 times lower than used previously ...
... EntreMed, Inc.,(Nasdaq: ENMD ), a clinical-stage ... and inflammatory diseases, today,announced that on April 4, ... Qualifications Department of the NASDAQ Stock Market, LLC. ... "Minimum Bid,Price Requirement," stated that the Company,s common ...
Cached Biology Technology:ARIUS recognized for entrepreneurial excellence 2Nanosized technology has supersized effect on tumors 2Nanosized technology has supersized effect on tumors 3EntreMed Receives Nasdaq Deficiency Notice 2EntreMed Receives Nasdaq Deficiency Notice 3EntreMed Receives Nasdaq Deficiency Notice 4
(Date:10/15/2014)... of Life, is a non-traditional biophysics textbook and it ... is a journey of discovery into biological systems and ... biological regulation. It is about how our genes make ... the billions of cells in an organism. It quantifies ... principles, which can be found on both large and ...
(Date:10/15/2014)... and to an unexpected extent. The outbreak does not ... virus shows a new disease dynamic in regions, where ... the German National Academy of Sciences Leopoldina, acatech – ... Union of the German Academies of Sciences and Humanities ... , In the statement the academies call for the ...
(Date:10/15/2014)... , Oct. 15, 2014 NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce market releases photos ... in Times Square on Monday October 13 th . ... David Tunnel and angel investor Mr. Chad A. ... , CEO of NXT-ID thanked his investors and employees "for their ...
Breaking Biology News(10 mins):New book about life as seen from physics 2Academies call for consequences from the Ebola virus epidemic 2Academies call for consequences from the Ebola virus epidemic 3Academies call for consequences from the Ebola virus epidemic 4Academies call for consequences from the Ebola virus epidemic 5Photo Release: NXT-ID Inc. Rings Opening Bell of the NASDAQ Stock Market October 13th 2Photo Release: NXT-ID Inc. Rings Opening Bell of the NASDAQ Stock Market October 13th 3
... Congress demonstrated that initial treatment with adalimumab (Humira, ADA) plus ... disease control in many patients, and may also offer the ... Results of a study of 1032 patients with early (less ... after 26 weeks with ADA 40mg every other week + ...
... an economically and environmentally beneficial, ,bio-derived, Australian and ... proposition, according to a report compiled by CSIRO ... players.The report, Flight Path to Sustainable Aviation, predicts ... sustainable, Australia-New Zealand aviation fuels industry could cut ...
... Many kinds of algae and cyanobacteria, common water-dwelling microorganisms, ... water molecules and release hydrogen, which holds promise as ... reason this approach hasn,t yet been harnessed for fuel ... a back seat to the production of compounds that ...
Cached Biology News:Targeted adalimumab treatment can optimize long-term outcomes for patients with early RA 2Sustainable 'bio-derived' jet fuel industry is achievable 2MIT: Teaching algae to make fuel 2
... utilizies CTI Molecular Imaging's proprietary Focus™ ... sensitivty, and a large imaging volume ... to image multiple mice or large ... a dedicated small animal PET (Positron ...
... StatMatic I provides a convenient and affordable ... work. Used with an eight-port disposable manifold, ... possible with multi-channel pipettes. The eight-port manifold, ... volumes of 100, 200, 250, or 300mL ...
... Stabilizing Diluent (MOPS Buffered) has been developed ... conjugates in solution. HRP Stabilizer prevents ... the conformation of the antibody or protein ... is filtered at 0.2 microns., ,Contents: ...
384 Well PCR Plate Carrier for Thermo-Sealer...
Biology Products: